SynthX Center
Houston
About SynthX Center
Synthesis X (SynthX) is to develop groundbreaking cancer drugs and technologies by leveraging innovations in the synthesis of molecules and materials from the fields of organic chemistry, chemical biology, and nanomaterial synthesis, in collaboration with cancer programs at the Texas Medical Center (TMC).
Company Facts
- Operating status: Active
- IPO status: Private
- Total funding: $18.0M
- Last round: Grant (Jan 2026)
- Website: synthx.rice.edu
- Phone: 713-348-0000
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/synthx-center-109821 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.